Cyclophosphamide in the treatment of pulmonary diseases: Survey of use, training, and practitioner knowledge base

Chest

Volumn 116, Issue 5, 1999, Pages 1159-1162

  Cozzi, Phillip J ^a   Hall, Jesse B ^b  

^a Elmhurst Memorial Healthcare   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cyclophosphamide; Knowledge base; Survey; Training

Indexed keywords

CYCLOPHOSPHAMIDE;

ARTICLE; BRONCHIOLITIS; DRUG INDICATION; DRUG USE; GOODPASTURE SYNDROME; HUMAN; INTERSTITIAL PNEUMONIA; LUNG DISEASE; MEDICAL SOCIETY; PRESCRIPTION; PRIORITY JOURNAL; PULMONOLOGY; VASCULITIS;

EID: 0032718083     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.116.5.1159     Document Type: Article

References (5)

1. 1 Fox DA, McClune WJ. Immunosuppressive drug therapy of systemic lupus erythematosis. Rheum Dis Clin North Am 1994; 20:265-299
2. 2 Lynch JP, McClune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997; 155:395-420
3. 3 Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20-year follow-up study. Arthritis Rheum 1995; 38:1120-1127
4. 4 Fauci AS, Haynes BF, Katz P, et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98:76-85
5. 5 Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488-498